🇺🇸

US SEC Filing Intelligence

Daily AI-powered analysis of SEC EDGAR filings, FDA approvals, and US regulatory disclosures. Investment signals, risk flags, and sector themes for US markets.

·daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 27, 2026

Across 50 filings in the S&P 500 Consumer Discretionary stream (with outliers in energy/commodities, infra, and finance), proxy season dominates with 15+ DEF/DEFA14A filings signaling May 2026 AGMs for firms like Marriott, Ford, Equifax, and Haverty, focusing on director elections, comp approvals, and governance amid mixed 2025 results. Period-over-period trends show modest revenue growth in retail/furniture (Haverty +5% YoY sales, Lifeloc +6%), but sharp declines in commodity funds (oil/gas ETFs assets down avg 20% YoY, e.g., US 12 Month Oil -25.8%), widening losses in graphite/mining (GrafTech net loss to $219.8M from $131.2M), and narrowing losses in biotech (Werewolf -14% YoY). M&A activity surges with 8 deals/tenders (Great Lakes $17/share tender, JFB/XTEND $1.5B combo with $71M backlog/$500M pipeline, Shizuoka-Nagoya integration), signaling consolidation for synergies. Capital allocation leans conservative (dividends up at Community Financial 33rd year +2.2%, LM Funding >3.3M shares repurchased), with strong balance sheets (Haverty zero debt/$125M cash). Forward-looking catalysts cluster in mid-2026 M&A closings and Q1 2026 production ramps (Lifeloc SpinDetect), but risks from cash burn (Werewolf runway to Q4 2026) and covenant relaxations (OFS min NII cut to $1M). Overall, defensive retail outperforms volatile commodities, favoring M&A plays over pure consumer exposure amid cautious spending.

25 high priority25 medium50 total filings
·daily

S&P 500 Healthcare Sector SEC Filings — March 27, 2026

In the S&P 500 Healthcare stream, biotech filings dominate with widespread cost discipline driving net loss narrowing averaging 42% YoY across Werewolf Therapeutics (-14% to $60.8M), Kezar Life Sciences (-33% to $56M), Humacyte (-73% to $40.8M), and Alamar Biosciences (-37% to $29.8M), fueled by R&D cuts of 20-49% and G&A reductions of 17-21%. Revenue acceleration shines in diagnostics and providers: Alamar +195% YoY to $74.2M, IDEXX Laboratories +10% with EPS +23% to $13.08, Elevance Health +13% to $197.6B. Clinical catalyst from Kodiak Sciences' Phase 3 superiority in diabetic retinopathy offsets patent reaffirmation favoring Broad Institute at Editas Medicine. Cash runways vary, with Werewolf limited to Q4 2026 prompting strategic review incl. sale/merger. Mature firms prioritize returns (Elevance $4.1B repurchases/dividends) amid proxy season recaps. Portfolio implications: Biotech turnaround via op ex efficiency supports overweight on revenue-generating names like IDEXX/Humacyte; monitor IPOs, trials, and May AGMs for catalysts amid mixed sentiment (positive in 4/9 key health filings).

32 high priority18 medium50 total filings
·daily

US Executive Compensation Proxy SEC Filings — March 27, 2026

Across 50 DEF 14A proxy statements filed around March 27, 2026, for US companies' 2026 annual meetings (mostly May-June), overarching themes include robust 2025 performance highlights in ~25 filings with average YoY revenue growth of ~10% (range 4-32%), dividend increases in 6 companies (e.g., PepsiCo's 54th consecutive, CRH +6%), and capital returns via buybacks ($400M Indivior, $1.2B CRH), signaling management confidence amid mixed sentiment (20 positive, 15 neutral, 10 mixed, 5 unspecified). Period-over-period trends show revenue expansion in sectors like REITs (Public Storage $4.8B record), tech/biotech (Teradyne $3.19B, Nurix $84M collab revenue), and industrials (Everus +32% to $3.75B), but margin pressures or sales declines in 8 cases (e.g., GrafTech -6% sales, Haverty net income -1.1%). Insider activity is limited but notable prohibitions on hedging/pledging in 5 filings (Southwest, Ford), high ownership in family-controlled firms (Tootsie Roll Class B dominance, PC Connection 56.6%), and no widespread selling patterns. Forward-looking catalysts cluster in May 2026 meetings for director elections, say-on-pay votes (all advisory), and auditor ratifications, with strategic shifts like PepsiCo portfolio reshaping and IDEXX CEO transition. Portfolio-level, bullish signals dominate consumer/industrial names with TSR outperformance (W.P. Carey +25%), while energy shows modest growth (Murphy Oil +3% production); implications favor long positions in high-growth outperformers pre-meeting voting risks.

50 high priority50 total filings
·daily

US IPO Pipeline SEC S-1 Filings — March 27, 2026

The IPO pipeline shows a surge in biotech S-1 filings (Kailera, Alamar, FibroBiologics, VivoSim), highlighting clinical-stage companies with narrowing net losses (e.g., Kailera -32% YoY to $149M, Alamar reduced to $29.8M) but surging R&D expenses (Kailera +15x) and no revenues, amid mixed sentiments. Revenue standouts include Alamar's 195% YoY growth to $74.2M and 385% gross profit expansion, contrasting Yesway's flat inside sales (0.4% YoY) and -1.9% fuel volume decline in Q1 2026 prelims. M&A activity features Allegiant's mixed pro forma merger with Sun Country (revenue +44% to $3.7B but net loss widening slightly) and Avalanche's SPAC combo with $216M PIPE. SPAC IPO (Collective II) and post-IPO resales (WaterBridge) add neutral liquidity plays, while VivoSim and Fibro face acute risks (going concern, Nasdaq delisting). Portfolio trends reveal biotech loss compression averaging ~30% YoY but high dilution/execution risks; actionable now: monitor IPO pricing amid 2026 market volatility.

10 high priority10 total filings
·daily

Global High-Priority Regulatory Events — March 27, 2026

Across 50 filings in the 'Global High Priority Market Events' stream, dominant themes include M&A activity (e.g., mergers, spin-offs, amalgamations), regulatory non-compliances and penalties (prevalent in Indian firms), distress signals like debt defaults, delisting risks, and going concern doubts in biotechs, alongside positive credit facilities and IPOs/SPACs. Period-over-period trends show mixed revenue performance: standout growth in Alamar Biosciences (+195% YoY to $74.2M), Sportradar (+17% to €1,290M), Equifax (+7% to $6.075B), and Indivior (+4% to $1.24B), but sharp declines in Origin Materials (-40% FY2025 to $18.9M) and Sarda Proteins (revenue to 57,627 Lakhs from 97,596 Lakhs). Biotech sector exhibits bifurcation with AnaptysBio spin-off ($180M cash runway) contrasting VivoSim and BiomX distress; financials see refinancing positives (Enterprise $1.5B facility, Delek new credit agreement). Critical implications: heightened insolvency risks in infrastructure/Indian firms (IL&FS default, Shirpur/Setubandhan CIRP), M&A catalysts for value unlock (Two Harbors $10.80/share takeover, Bank of Nagoya integration), and proxy-driven governance shifts (Norwegian Cruise board refresh). Portfolio-level patterns flag Indian regulatory fines averaging ~₹5-12L across 5+ firms, biotech cash runways extending to 2027 with dilution risks, and energy/REITs prioritizing capital returns amid stable metrics.

50 high priority50 total filings
·daily

US Earnings Financial Results SEC Filings — March 27, 2026

Across 50 10-K filings for FY ended Dec 31, 2025, a stark divide emerges: 30+ ABS trusts (Ally Auto, Exeter Auto, Navient/SLM Student Loan) confirm full servicing compliance with neutral sentiment and no material issues or metrics, signaling stability in securitized auto/student loan markets. Operating companies (20 filings) reveal volatile growth, with digital asset firms (BitGo +424% YoY revenue to $16.2B, FG Nexus +210% to $2.4M, American Bitcoin +159% to $185M) driving top-line surges but massive net losses from unrealized digital asset impairments (e.g., BitGo -$14.8M vs +$156K prior). SPACs/blank checks (OTG, Republic Digital, Galata II, Launch Two) hold steady trusts yielding interest income (e.g., Launch Two net income +302% YoY to $8.9M), while biotech/tech (Luminar -12% rev, Cyngn -40%, Phunware -20%) face revenue declines and cash burns amid narrowing losses in some (Instil Bio -4% loss improvement, Werewolf -14%). Portfolio trends show average revenue growth +100% YoY in crypto-exposed names but -15% in traditional tech/biotech; cash positions deteriorated in 12/20 operating cos (avg -40% YoY), flagging liquidity risks. No insider trading patterns or M&A noted; steady dividends rare (United Guardian $0.60/share). Implications: Favor crypto growth plays for rebound potential, avoid bleeding tech, monitor trusts for any compliance cracks.

50 high priority50 total filings
·daily

US SEC Trading Suspension Halt Orders — March 27, 2026

A cluster of 7 small-cap US-listed companies disclosed Nasdaq or NYSE deficiency notices dated March 24-27, 2026, primarily for bid prices below $1.00 over 30 consecutive business days (6/7 cases), with additional issues like late 10-Q filings (Immersion) and deficient stockholders' equity (BiomX). No immediate trading suspensions or delistings, but uniform 180-day cure periods extend to September 2026, with potential second extensions if other standards met. Sentiment is negative across 6/7 filings (Immersion mixed due to dividend declaration), highlighting acute microcap distress without evident period-over-period financial improvements in summaries. Common forward-looking strategies include monitoring bid prices and pursuing reverse stock splits (explicitly noted in 5/7), signaling management efforts to avert OTC migration. Portfolio-level pattern reveals Nasdaq-heavy (5/7) vulnerability in consumer goods, tech services, biotech, and haptics sectors, with no insider buying or bullish capital allocation trends beyond one dividend. Implications include heightened short-term volatility, delisting overhang suppressing multiples, and alpha potential in reverse split bounces or shorts on non-compliance.

7 high priority7 total filings
·daily

US Corporate Distress Financial Stress SEC Filings — March 27, 2026

Across 47 filings in the USA Corporate Distress & Bankruptcy stream, a mix of distress signals and resilience emerges, with 9 companies (HAIN, Alight, ZW Data, SOPA, IMMERSION, BiomX, GIFTIFY, AMERICAN REBEL, BIOMX) facing Nasdaq/NYSE listing deficiencies primarily from sub-$1 bid prices over 30 days, alongside Iterum Therapeutics' bankruptcy petition, but offset by 20+ positive financings, refinancings, and M&A (e.g., TWO Harbors merger at $10.80/share, i-80 Gold $150M prepay). Period-over-period trends are sparse but highlight distress in Origin Materials (Q4 rev -67% YoY to $3M, FY rev -40% to $18.9M, op ex +1100% YoY Q4 due to $178.8M impairment) and covenant relaxations (OFS Capital tangible net assets covenant cut 25% to $75M). Portfolio-level patterns show small-cap biotechs/techs vulnerable to delistings (8/47), while energy/finance firms (Delek, Enterprise Products, Puget Energy) secure larger facilities ($450M-$1.5B), signaling sector rotation opportunities. Forward-looking catalysts cluster in April 2026 (Anaptys spin-off 4/20, Cartesian redemption pre-domestication, Nasdaq cures by Sep). Capital allocation leans defensive (dividends continued pre-merger at TWO, Immersion $0.075/share), with insider alignment via lockups (Streamex co-founders 1-yr voluntary). Overall, distress concentrated in microcaps, but refinancings indicate manageable liquidity for larger names, urging watch on compliance deadlines.

47 high priority47 total filings
·daily

US Executive Officer Management Changes SEC — March 27, 2026

Across 50 filings in the USA Executive & Director Changes stream (events March 23-27, 2026), a surge in C-level transitions (10+ CEO/CFO changes) and director resignations/not-for-re-election announcements (20+ instances) signals portfolio-wide leadership churn, predominantly neutral with no disagreements cited in 95% of cases. Positive hires in growth-oriented firms like Rumble (AI-savvy CFO), Sturm Ruger (finance transformation expert CFO), MaxCyte (20+ yrs finance CFO), and NCLH (new CEO with $48M equity package tied to TSR CAGR >5-20%) highlight conviction in scaling amid sector tailwinds; negative outlier in Nuwellis (director resignations citing info access disputes). No broad period-over-period financial deterioration evident, but 2026 incentive plans reveal forward thresholds like JAKKS EBITDA >$35.6M (tiered up to $65.6M max bonus), Fuel Tech OI >$250K pool funding, First Industrial FFO/NOI targets (55/30% weighting), implying stable-to-modest growth expectations absent YoY declines. Activist-driven board refreshes (e.g., NCLH/Elliott adding 5 independents) and planned retirements (e.g., SBA EVP Dec 2026) dominate, with mixed comp signals like Traeger discretionary bonuses despite 2025 misses. Implications: Monitor interim leadership risks in biotechs/fintech; bullish for cruise/tech with strong hires; sector churn neutral but flags governance watch in small-caps.

50 high priority50 total filings
·daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — March 27, 2026

The USA Bankruptcy & Insolvency intelligence stream highlights a single critical filing from Iterum Therapeutics plc, signaling imminent corporate dissolution amid acute financial distress. Key drivers include severely limited cash resources, ongoing Nasdaq listing non-compliance, failed acquisition discussions for sulopenem, and modest ORLYNVAH sales insufficient to cover high operating costs, with no period-over-period data indicating any positive revenue growth or margin expansion. The Irish High Court petition for winding up, filed March 27, 2026, led to the appointment of Joint Provisional Liquidators Damien Murran and Jennifer McMahon, who may withdraw ORLYNVAH from the U.S. market and oversee subsidiary wind-downs. This development carries maximum materiality (10/10) and uniformly negative sentiment, implying near-total equity value destruction, potential delisting, and disrupted commercialization efforts. Portfolio-level implications point to elevated insolvency risks in small-cap biotech, where cash burn outpaces revenue generation, warranting immediate short positioning or avoidance.

1 high priority1 total filings
·daily

US Corporate Board Director Changes SEC Filings — March 27, 2026

Across 50 SEC filings on USA Board Room Changes dated March 27, 2026, the dominant theme is elevated executive and board turnover, with 22 resignations/terminations/non-re-elections (44%), 18 appointments/promotions (36%), and 10 compensation/plan updates (20%), signaling transitional instability particularly in biotech/pharma (12/50 filings) and small-caps. Sentiment skews neutral (80%), with positive tones on strategic hires (e.g., Rumble CFO from Intel, Sturm Ruger CFO transition) and mixed/negative on sudden exits (e.g., Cue Biopharma CEO, Nuwellis director disputes). No explicit YoY/QoQ financial deteriorations noted, but interim leadership in 8 cases (e.g., One World, Reed's, Genesco) flags potential execution risks amid bonus plans tied to EBITDA/FFO targets in 5 firms. Activist-driven changes at NCL (board expansion to 9, 4 resign/5 appoint) highlight governance shakeups. Portfolio implications: Monitor small-cap biotechs for volatility; positive hires suggest growth conviction in tech/industrials. Overall, 14 high-materiality events (7-9/10) warrant near-term scrutiny for stock catalysts around AGMs.

50 high priority50 total filings
·daily

US Merger & Acquisition SEC Filings — March 27, 2026

The 18 filings reveal a dominant SPAC ecosystem frenzy with 15/18 documents from blank check companies, highlighting IPO completions (BHAV $102M total proceeds, Blue Water IV $134.25M, TRG partial over-allotment to $206.32M total), trust extensions (Ribbon $125K 1-month, Rising Dragon $50K note, IB to Sep 2026, International Media 16th extension to May 2026, Columbus $50K to Apr 2026), and leadership churn (resignations/appointments at AltEnergy, Charlton Aria, Goldenstone). Actual M&A progress includes ETHZilla's $150M 5-year revolving loan purchase commitment (initial $1.44M acquired), Contango ORE's completed 50/50 merger with Dolly Varden yielding >$100M cash/minimal debt, Pelican Holdco's pending merger with loss-making March GL (going concern doubts, $1.67M assets), and Drugs Made's sponsor transition for AI/cyber target with $500K funding commitment. No broad period-over-period trends due to non-operating status of most SPACs, but aggregate fresh trust deposits exceed $500M from IPOs/extensions, signaling robust dry powder for de-SPAC deals into Q2 2026. Neutral-to-positive sentiment prevails (12/18 positive/neutral), with mixed cases tied to distress; portfolio implication is heightened M&A liquidity but execution risks from extensions/churn.

18 high priority18 total filings
·monthly

US Pre-Market SEC Filings Roundup — March 27, 2026

Overnight SEC filings from March 26-27, 2026, feature 50 documents dominated by proxy statements (DEFA14A/DEF 14A) for May 2026 AGMs across airlines, oil, pharma, and biotech, signaling routine governance but with embedded FY2025 highlights showing mixed performance. Period-over-period trends reveal revenue growth in 8/15 10-Ks (e.g., Sportradar +17% YoY, BitGo +424% YoY, Apollo investment income +1,540% YoY) offset by declines in 7/15 (Luminar -12% YoY, Phunware -19.9% YoY, SpringBig -7.4% YoY), with margin expansions in Indivior (+500 bps to 35%) and Sportradar (+480 bps profit margin) but compressions elsewhere. Biotech shines with clinical wins (Kodiak Phase 3 success, Nurix 83% ORR), while credit funds maintain stable leverage (0.57x-0.82x) and distributions; SPACs/BLANKS show IPO completions and amendments amid no revenues but trust growth. Capital allocation leans shareholder-friendly (Indivior $400M buyback, Oaktree $0.16/share distro, News Corp $1B repurchase), but management churn (resignations at One World, AltEnergy) raises flags. Portfolio-level: Energy/oil mixed (Murphy +3% prod YoY), tech/autonomy challenged (Luminar assets -64% YoY), potential M&A (Brown-Forman/Pernod) as top catalyst. Actionable: Favor biotech/credit longs pre-AGMs, monitor SPAC redemptions.

28 high priority22 medium50 total filings
·daily

S&P 500 Technology Sector SEC Filings — March 26, 2026

Across 13 filings from the S&P 500 Technology stream (with some cross-sector inclusions), dominant themes include neutral proxy statements for upcoming AGMs, mixed financial results highlighting cost discipline amid revenue softness, and selective growth in reserves/operations. Period-over-period trends show revenue declines averaging -5% YoY in reporting companies (e.g., Arcadia -4% FY2025, Q4 -26%), offset by operating expense cuts (Arcadia -15% FY, Mueller +24.4% op income YoY), with outliers like Mueller's record +10.9% sales and +26.5% net income. Critical developments: Mueller's 2030 plan targeting $1.5B op income, Arcadia's terminated deal and $2.1M cash infusion for growth, AParadise SPAC progress toward ENHA NYSE listing, and Canadian Natural's +4.5% proved reserves to 15,910 MMBOE. No insider trading activity reported across filings, limiting conviction signals; capital allocation shines with Mueller's $244M buybacks and 25% dividend hike. Portfolio implications: Tech exposure limited to stable Apple passive stake; monitor governance votes and May catalysts for alpha in industrials/biosciences proxies. Overall, cautious optimism from improving losses (+31-46% YoY in Arcadia) and strategic plans amid cash pressures.

7 high priority6 medium13 total filings
·daily

Nasdaq 100 Stocks SEC Filings — March 26, 2026

Across 24 NASDAQ-100 related SEC filings from March 26, 2026, overarching themes include cost discipline driving narrower losses in biotech/agrotech (Arcadia Biosciences FY loss improved 31% YoY to $2.3M, MetaVia net loss down 53% to $13M), robust industrial performance (CMC Q2 FY26 EBITDA +114% YoY to $297.5M, Mueller 2025 net income +26.5% YoY to $765M), and financing for growth (Keurig $5.55B notes for JDE Peet’s acquisition, Arcadia $2.1M proceeds). Period-over-period trends show mixed revenues (4/10 with declines avg -15% YoY, e.g., Arcadia -4% FY), but operating expenses down avg 25% YoY across reporting firms, boosting margins in winners like CMC (+610 bps to 14%). Resource firms added reserves (Canadian Natural +4.5% to 15,910 MMBOE via acquisitions), while proxies signal governance evolution (Murphy USA declassification). Neutral 13G amendments from Vanguard indicate passive shifts without ownership changes. Critical implications: Industrials offer strength amid sector rotation, biotechs present turnaround plays with cash runways into late 2026, but leverage risks loom in deals like Keurig's.

11 high priority13 medium24 total filings
·daily

S&P 500 Financials Sector SEC Filings — March 26, 2026

Across 50 SEC filings from the USA S&P 500 Financials stream (primarily banks, insurers, REITs, asset managers amid broader microcap/SPAC noise), sentiment skews mixed/neutral (32/50 filings), with 12 companies reporting YoY revenue growth averaging +13% (e.g., Lumexa +7.8%, Leef Brands +22.1%) offset by 11 declines averaging -28% (e.g., CaliberCos -60.7%, STRATA -9%). Net losses narrowed in 9 firms (avg improvement 35%) but widened in 8 (avg +18%), highlighting persistent profitability challenges despite asset growth in credit investors (MSD +40.7%, AB Private +16.9%). SPAC/de-SPAC and M&A activity dominates (18 filings), signaling Q2 2026 catalysts with $500M+ proceeds (e.g., Xanadu, Suncrete). Capital allocation leans conservative: dividends in REITs (BlackRock $0.96/share), buybacks/dividends in retail proxies (Williams Sonoma $862M buybacks + $327M divs), no major cuts. Forward-looking guidance stable (Lumexa reiterates 2026 rev $1.045-1.097B), but risks from delistings (FiscalNote), going concerns (Indigo SPAC), and leverage rises. Portfolio implications: Bullish on SPAC mergers and credit growth; bearish on revenue-dependent microcaps; watch NIM/ROE trends in banks/insurers for rate sensitivity.

37 high priority13 medium50 total filings
·daily

S&P 500 Consumer Staples Sector SEC Filings — March 26, 2026

Across 50 filings in the USA S&P 500 Consumer Staples stream (with broader exposure via trusts and adjacents), proxy statements dominate (e.g., ADM, Newell, Philip Morris, Oshkosh) signaling peak governance season with May 2026 AGMs, board recommendations FOR comp plans/auditors amid neutral sentiment. Period-over-period trends show mixed revenue growth (e.g., Insight Molecular +116% YoY, Interlink +1.8% YoY, Worthington Steel +12% Q3 YoY) offset by widespread margin compression (Interlink gross -270bps YoY, Rockwell Q4 flat at 21% but FY sales -32% YoY) and cash deteriorations (Eltek ops cash -75% YoY to $1.1M, Rockwell ops cash used $659k vs provided $4.2M prior). Capital allocation leans shareholder-friendly in outliers (Oshkosh dividend +11.8% to $0.57, cash returned +73% YoY) but debt-heavy for M&A (Keurig €3B+$2.55B notes for JDE Peet’s). Forward-looking catalysts cluster in FDA reviews (Insight Q3 2026), acquisitions (Keurig by Feb 2027), and AGMs, with bullish alpha in diagnostics/health adjacents but bearish pressures from macro risks (Kornit inflation/overcapacity). Portfolio-level: 12/50 filings show revenue growth >10% YoY, but 8/20 with margin data average -150bps compression; staples-specific neutral on governance, mixed on financing.

29 high priority21 medium50 total filings
·daily

S&P 500 Industrials Sector SEC Filings — March 26, 2026

Across 50 SEC filings from the USA S&P 500 Industrials stream (broadly including adjacent sectors like materials and construction amid sparse pure industrials), proxy season dominates with 15+ DEF/DEFA14A filings scheduling May 2026 annual meetings, signaling routine governance amid neutral-to-positive sentiment on board refreshes and comp approvals. FY2025 financials reveal mixed trends: revenue growth in select names like Paychex (+19.8% YoY Q3) and Iridex (+8% FY), but widespread loss widening in biotechs (e.g., Acumen +19%, Upstream +128%) and margin pressures (e.g., Evogene gross loss from inventory impairment); banks show NIM expansion (Farmers & Merchants +34 bps to 3.02%) offset by deposit declines (-5%). Capital returns shine with Newmont's $1.1B dividends/$3B buybacks and Banc of California's 8% share repurchase, while forward catalysts cluster in Q2 2026 (Rhythm EMA approval, multiple AGMs). Portfolio-level patterns include cost discipline (R&D/G&A cuts in 7/12 10-Ks averaging -25% YoY) amid cash burn, biotech regulatory tailwinds, and M&A like Corebridge-Equitable all-stock deal for $1.5T AUM scale. Implications: tactical buys in outperforming industrials like GE (passive Vanguard stake) and Newmont, caution on biotech cash drains; alpha from May proxy-driven volatility and Q2 catalysts.

27 high priority23 medium50 total filings
·daily

S&P 500 Energy Sector SEC Filings — March 26, 2026

Across 12 SEC filings in the USA S&P 500 Energy intelligence stream (including midstream and LNG players like Targa Resources, Williams Companies, and Golar LNG), overarching themes include robust revenue growth in select reporters (e.g., Golar LNG +51% YoY, Galapagos NV +304% YoY) offset by rising costs, impairments, and margin pressures, with Williams Sonoma net earnings -3.3% YoY despite +1.2% revenue. Governance activity dominates with multiple proxy statements and board changes, notably Williams Companies reducing board size post-Alan Armstrong's resignation for U.S. Senate role, signaling leadership transitions in energy midstream. Capital allocation shows shareholder returns via buybacks ($862M at Williams Sonoma) and dividends ($327M), alongside capital raises like Peapack-Gladstone's $50M preferred stock. Forward-looking catalysts cluster around April-May 2026 AGMs and events like Enhanced Games launch, amid mixed sentiment (5/12 mixed or negative). Portfolio-level trends reveal 3/5 financial reporters with YoY revenue acceleration (avg +119%) but operating challenges (e.g., Golar expenses +31%, Galapagos R&D +37%), implying selective growth opportunities in energy services/LNG versus broader cost headwinds. Market implications favor monitoring midstream governance stability and LNG revenue momentum for near-term positioning.

10 high priority2 medium12 total filings
·daily

US Material Events SEC 8-K Filings — March 26, 2026

Across 50 US SEC 8-K filings dated March 26, 2026, the dominant themes are pervasive executive turnover (20+ resignations/appointments across C-suite and boards), aggressive financing activity ($7M PIPE at Health In Tech, $475.9M at Wolfspeed, $250M credit at Stone Point), major M&A/divestitures (OLAPLEX buyout at 55% premium, Equitable-Corebridge $22B merger, SSR Mining $1.5B sale), and debt restructurings/extensions signaling liquidity strains in smaller caps. Limited period-over-period data shows Interlink Electronics with Q4 2025 revenue -4.5% YoY to $2.853M, gross margins -790 bps to 31.7%, but FY revenue +1.8% to $11.89M; no broad portfolio trends due to event-driven nature, but positive capital raises contrast one bankruptcy (Broad Street Realty). Critical developments include accretive mergers (Equitable-Corebridge >10% EPS accretion by 2028E), premium acquisitions, and experienced exec hires (Bloom Energy CFO, Vitesse CEO), implying sector transitions in energy/tech/finance; bearish signals from resignations and debt waivers highlight turnover risks. Market implications: Opportunities in M&A catalysts and post-financing pops, but watch liquidity/distress in microcaps amid high dilution risks.

50 high priority50 total filings
← All geographies